ReviewEuropean journal of medical research2025
NETs in ovarian cancer progression: innovative nanoparticle-based therapeutic strategies.
Review in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preoperative Inflammatory Markers as Predictors of Ovarian Tumor Malignancy: A Retrospective Diagnostic Study.Medicina (Kaunas, Lithuania) · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is an aggressive and heterogeneous malignancy characterized by genetic diversity, clonal evolution, and rapid development of therapeutic resistance, representing a major global clinical challenge. Neutrophils actively drive disease progression by fostering tumor growth, angiogenesis, immune evasion, and metastasis through the formation of neutrophil extracellular traps (NETs). NETs accelerate epithelial-to-mesenchymal transition (EMT), remodel the extracellular matrix (ECM), and prime pre-metastatic niches, creating a permissive environment for metastatic dissemination. Elevated NET levels correlate with advanced disease and poor prognosis, positioning them as powerful diagnostic and prognostic biomarkers. To exploit this vulnerability, we propose a multifunctional nanoparticle platform co-delivering GSK484, a selective anti-NETosis agent, alongside a potent cytotoxic drug. Engineered for tumor-selective targeting and pH-responsive release, this system dismantles the NET-rich tumor microenvironment while directly eradicating cancer cells, maximizing local efficacy and minimizing systemic toxicity. By simultaneously neutralizing the NET-modified niche and attacking tumor cells, this strategy has the potential to overcome chemoresistance, block metastatic spread, and enable precision-guided therapy. Implementation of this approach could refine patient stratification, enhance response rates, reduce recurrence, and translate into tangible survival benefits. This review highlights NETs as central orchestrators of ovarian cancer progression and presents a translationally actionable nanomedicine strategy poised to transform clinical outcomes in a malignancy long plagued by therapeutic failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.